Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
This pharmacoepidemiologic study was conducted to determine whether risk factors for upper gastrointestinal bleeding influenced the prescription of cyclo-oxygenase (COX)-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) at the time when COX-2 inhibitors were first included in the formulary of reimbursed medications. A population-based case-control study was conducted in which the prevalence of risk factors and the medical histories of patients prescribed COX-2 inhibitors and traditional nonselective NSAIDs were compared. The study population consisted of a random sample of members of the Quebec drug plan (age 18 years or older) who received at least one dispensation of celecoxib (n = 42,422; cases), rofecoxib (n = 25,674; cases), or traditional nonselective NSAIDs (n = 12,418; controls) during the year 2000. All study data were obtained from the Quebec health care databases. Adjusting for income level, Chronic Disease Score, prior use of low-dose acetylsalicylic acid, acetaminophen, antidepressants, benzodiazepines, prescriber specialty, and time period, the following factors were significantly associated with the prescription of COX-2 inhibitors: age 75 years or older (odds ratio [OR] 4.22, 95% confidence interval [CI] 3.95-4.51), age 55-74 years (OR 3.23, 95% CI 3.06-3.40), female sex (OR 1.52, 95% CI 1.45-1.58), prior diagnosis of gastropathy (OR 1.21, 95% CI 1.08-1.36) and prior dispensation of gastroprotective agents (OR 1.57, 95% CI 1.47-1.67). Patients who received a traditional nonselective NSAID recently were more likely to switch to a coxib, especially first-time users (OR 2.17, 95% CI 1.93-2.43). Associations were significantly greater for celecoxib than rofecoxib for age, chronic NSAID use, and last NSAID use between 1 and 3 months before the index date. At the time of introduction of COX-2 inhibitors into the formulary, prescription channeling could confound risk comparisons across products.
Moride
Yola
Y
Faculty of Pharmacy, Université de Montréal, Montreal, Canada. yola.moride@umontreal.ca
Ducruet
Thierry
T
Boivin
Jean-François
JF
Moore
Nicholas
N
Perreault
Sylvie
S
Zhao
Sean
S
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D016022:Case-Control Studies; D000068579:Celecoxib; D015986:Confounding Factors, Epidemiologic; D000075202:Contraindications; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016208:Databases, Factual; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D004363:Drug Utilization; D005260:Female; D005569:Formularies as Topic; D005756:Gastritis / Q000453:epidemiology; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D019458:Insurance Coverage; D007356:Insurance, Pharmaceutical Services; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use; D016015:Logistic Models; D008297:Male; D008511:Medicine; D008875:Middle Aged; D015999:Multivariate Analysis; D015995:Prevalence; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use; D011792:Quebec / Q000453:epidemiology; D012307:Risk Factors; D012494:Sampling Studies; D012737:Sex Factors; D013038:Specialization; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D013450:Sulfones / Q000009:adverse effects / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000068579:Celecoxib
JAMA. 1999 Nov 24;282(20):1921-8
10580457
J Clin Epidemiol. 1995 Aug;48(8):999-1009
7775999
JAMA. 1999 Nov 24;282(20):1961-3
10580464
Lancet. 1999 Dec 18-25;354(9196):2106-11
10609815
Arch Intern Med. 2000 Jun 26;160(12):1781-7
10871971
JAMA. 2000 Sep 13;284(10):1247-55
10979111
JAMA. 2000 Sep 13;284(10):1297-9
10980759
Arch Intern Med. 2000 Oct 23;160(19):2998-3003
11041909
N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528
11087881
JAMA. 2001 Aug 22-29;286(8):954-9
11509060
JAMA. 2002 Jan 2;287(1):64-71
11754710
BMJ. 2002 Jun 1;324(7349):1287-8
12039807
BMJ. 2002 Jun 1;324(7349):1289-90
12039808
Ann Pharmacother. 2002 Jul-Aug;36(7-8):1290-1
12086565
BMJ. 2002 Sep 21;325(7365):607-8
12242157
Ann Intern Med. 1991 Feb 15;114(4):257-63
1987872
J Clin Epidemiol. 1992 Feb;45(2):197-203
1573438
J Clin Epidemiol. 1994 Jul;47(7):731-7
7722586
JAMA. 1999 Nov 24;282(20):1929-33
10580458